Dry Powder Inhaler Device Market Share, Size, Analysis And Opportunity Assessment (2019 - 2026)

The global Dry Powder Inhaler Device Market is estimated to reach USD 912.3 Million by 2026, according to a new report by Reports and Data. This can be mainly associated due to increasing incidences of hereditary diseases, lung disorders and increasing pollution due to the high discharge of harmful chemicals are significant reasons for chronic respiratory diseases that are generating a significant demand for the dry powder inhalers. Improvised efficiency of dry powder inhalers and better results in comparison with alternative therapies is a driving factor that will aid market growth. Based on statistics, the rise in elderly population base inclined to respiratory infections will boost market growth. A significant cause of lung disorders in teenagers and adults is the addiction to nicotine. Increases in variations of hormones due to the changing lifestyle which can trigger the need for having an addiction are also significant factors stimulating Market demand.

Request for PDF Sample at: https://www.reportsanddata.com/sample-enquiry-form/1233

Further key findings from the report suggest

• The asthma segment is valued at USD 205.1 million in 2018 and is estimated to reach USD 299.2 million by 2026 at a CAGR of 4.7% during the forecast period, due to an increase in air pollution levels across the world and increase in the incidence of asthma particularly in developed countries.
• Lifestyle changes and rise in the occurrence of allergies and infections amongst the population has driven to an extended demand for dry powder inhalers in the overall market in Europe. Industrialization and excessive use of chemicals have further increased the occurrence of respiratory ailments in workers that have led to market development.
• Other regions such as APAC are estimated to register the highest CAGR of 5.1 %, during the forecast period. APAC is anticipated to have the fastest growth, due to a rapidly emerging medical infrastructure, increasing expenses on healthcare and rising medical tourism in developing nations such as China and India in this region.
• Key participants include 3M Company, Astrazeneca Plc., Chiesi Farmaceutici S.p.A., GlaxoSmithKline Plc, Novartis AG, Cipla Ltd., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, MannKind Corporation, and Vectura Group Plc.

Read more at: https://www.reportsanddata.com/report-detail/dry-powder-inhaler-device-market

Product Outlook (Volume, Thousand Units; and Revenue, USD Million; 2016-2026)

• Capsule based
• Blister based
• Reservoir/Cartridge based
• Others

End User Outlook (Volume, Thousand Units; and Revenue, USD Million; 2016-2026)

• Hospitals and pharmacies
• Retail pharmacies
• Drug stores

Application Outlook (Volume, Thousand Units; and Revenue, USD Million; 2016-2026)

• Asthma
• COPD
• Diabetes
• Hereditary diseases
• Other

Type Outlook (Volume, Thousand Units; and Revenue, USD Million; 2016-2026)

• Single dose
• Multi-dose

Ask for Discount at: https://www.reportsanddata.com/discount-enquiry-form/1233

Regional Outlook (Volume, Kilo Tons; and Revenue, USD Million; 2016-2026)

• North America
1. U.S.
• Europe
1. Germany
2. UK
• Asia Pacific
1. China
2. India
3. South-east Asia
• Latin America
1. Brazil
• MEA